Skip to main content

previous disabled Page of 8
and
  1. No Access

    Article

    Tumor lysis syndrome in induction therapy for acute myeloid leukemia before the rasburicase era

    Guidelines recommend rasburicase for high-risk patients to prevent tumor lysis syndrome (TLS). However, little information is available on the incidence and outcome of TLS in AML patients. We analyzed 145 pati...

    Yumiko Toda, Masahiro Ashizawa, Rui Murahashi in International Journal of Hematology (2024)

  2. No Access

    Article

    Updated comparable efficacy of cord blood transplantation for chronic myelomonocytic leukaemia: a nationwide study

    Chronic myelomonocytic leukaemia (CMML) is a haematological malignancy with a poor prognosis. Allogeneic haematopoietic stem cell transplantation remains the only curative approach. Without human leucocyte ant...

    Shuhei Kurosawa, Yoshimitsu Shimomura, Ken Ishiyama in Bone Marrow Transplantation (2024)

  3. No Access

    Article

    Association between human herpesvirus-6 encephalitis and antiviral prophylaxis after allogeneic hematopoietic stem cell transplantation in the letermovir era

    The impact of letermovir (LTV)—an anti-cytomegalovirus (CMV) drug—on human herpesvirus-6 (HHV-6) encephalitis is unclear. We hypothesized that LTV prophylaxis may increase the incidence of HHV-6 encephalitis b...

    Toshiki Terao, Ken-ichi Matsuoka, Shigeo Fuji in Bone Marrow Transplantation (2024)

  4. No Access

    Article

    Significance of absolute neutrophil count before allogeneic hematopoietic stem cell transplantation in adult patients with aplastic anemia

    The impact of absolute neutrophil count (ANC) before allogenic hematopoietic stem cell transplantation (HSCT) on the outcomes for patients with aplastic anemia (AA) remains unclear. We retrospectively evaluate...

    Yukinori Nakamura, Yoshitaka Zaimoku, Hiroki Yamaguchi in Annals of Hematology (2024)

  5. No Access

    Article

    Impact of antithymocyte globulin usage and risk stratification for posttransplant lymphoproliferative disorders in aplastic anemia patients after allogeneic hematopoietic cell transplantation

    Ryusuke Yamamoto, Nobuhiro Hiramoto, Ayumi Fujimoto in Bone Marrow Transplantation (2024)

  6. No Access

    Article

    Analysis of risk factors for fatal renal complications after allogeneic hematopoietic cell transplantation

    Various complications can influence hematopoietic cell transplantation (HCT) outcomes. Renal complications can occur during the early to late phases of HCT along with various factors. However, studies focusing...

    Ryu Yanagisawa, Hiroaki Koyama, Kimikazu Yakushi** in Bone Marrow Transplantation (2024)

  7. No Access

    Article

    Allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia not in remission

    Allogeneic hematopoietic cell transplantation (HCT) is the last option for long-term survival for patients with chemotherapy-refractory acute myeloid leukemia (AML). By using the Japanese nationwide registry d...

    Masamitsu Yanada, Satoshi Yamasaki, Tadakazu Kondo, Takahito Kawata in Leukemia (2024)

  8. No Access

    Article

    HLA haploidentical stem cell transplantation from HLA homozygous donors to HLA heterozygous donors may have lower survival rates than haploidentical transplantation from HLA heterozygous donors to HLA heterozygous donors: a retrospective nationwide analysis

    In HLA haploidentical stem cell transplantation, patients and donors usually share one HLA haplotype and have one different HLA haplotype (hetero-to-hetero). However, there are rare cases of transplantation fr...

    Keiko Fukunaga, Kazuhiro Ikegame, Hirohisa Nakamae in International Journal of Hematology (2024)

  9. No Access

    Article

    Comparison of MEAM, MCEC and LEED high-dose chemotherapy followed by autologous stem cell transplantation in relapsed/refractory diffuse large B-cell lymphoma: data from the Japan Society for Hematopoietic and Cellular Therapy Registry

    Risa Koresawa-Shimizu, Ritsuro Suzuki, Yasufumi Uehara in Bone Marrow Transplantation (2024)

  10. No Access

    Article

    Outcomes of allogeneic hematopoietic cell transplantation under letermovir prophylaxis for cytomegalovirus infection

    Cytomegalovirus (CMV) infection is a major infectious complication following allogeneic hematopoietic cell transplantation (allo-HCT). Although letermovir (LMV) prophylaxis dramatically reduces the incidence o...

    Katsuto Takenaka, Shigeo Fuji, Toshihiro Matsukawa, Naoyuki Uchida in Annals of Hematology (2024)

  11. No Access

    Article

    Impact of HLA disparity on overall mortality risk in patients with extensive chronic GVHD: The HLA Working Group of Japanese Society for Transplantation and Cellular Therapy

    Shigeo Fuji, Akitoshi Hakoda, Junya Kanda, Takahiro Fukuda in Bone Marrow Transplantation (2023)

  12. No Access

    Article

    External validation and extended application of the transplant conditioning intensity score in acute myeloid leukemia

    This study aimed to validate the utility of the transplant conditioning intensity (TCI) score in 1714 patients with acute myeloid leukemia (AML) undergoing allogeneic bone marrow or peripheral blood stem cell ...

    Masamitsu Yanada, Yoshimitsu Shimomura, Shohei Mizuno in Bone Marrow Transplantation (2023)

  13. Article

    Open Access

    Poor outcome of allogeneic transplantation for therapy-related acute myeloid leukemia induced by prior chemoradiotherapy

    Therapy-related acute myeloid leukemia (t-AML) is a therapeutic challenge as a late complication of chemotherapy (CHT) and/or radiotherapy (RT) for primary malignancy. Allogeneic hematopoietic stem cell transp...

    Hiroaki Araie, Yasuyuki Arai, Michiko Kida, Jun Aoki in Annals of Hematology (2023)

  14. No Access

    Article

    Substitution of calcineurin inhibitors with corticosteroids after allogeneic hematopoietic cell transplantation

    Combination of calcineurin inhibitors (CIs) with short-term methotrexate is a standard prophylactic regimen for graft-versus-host disease (GVHD). However, it is sometimes difficult to continue CIs due to adver...

    Shimpei Matsumi, Shun-ichi Kimura, Yuhei Nakamura in International Journal of Hematology (2023)

  15. No Access

    Article

    Plasma ubiquitin C-terminal hydrolase-L1 (UCH-L1) level as a blood biomarker of neurological damage after allogeneic hematopoietic cell transplantation

    Several biofluid-based biomarkers for traumatic brain injury show promise for use in diagnosis and outcome prediction. In contrast, few studies have investigated biomarkers for non-traumatic brain injury. We f...

    Yosuke Okada, Hideki Nakasone, Kazuki Yoshimura in International Journal of Hematology (2023)

  16. No Access

    Article

    Risk factors and outcome of Stenotrophomonas maltophilia infection after allogeneic hematopoietic stem cell transplantation: JSTCT, Transplant Complications Working Group

    Stenotrophomonas maltophilia (S. maltophilia) is an aerobic nonfermenting Gram-negative bacillus widely distributed in the environment that has inherent multidrug resistance to beta-lactam and carbapenem antibiot...

    Masuho Saburi, Kumi Oshima, Kuniko Takano, Yoshitaka Inoue in Annals of Hematology (2023)

  17. No Access

    Article

    Interim analysis of post-marketing surveillance of ravulizumab for paroxysmal nocturnal hemoglobinuria in Japan

    Ravulizumab is a long-acting C5 inhibitor available for treating paroxysmal nocturnal hemoglobinuria (PNH). Post-marketing surveillance (PMS) was implemented following its approval in September 2019 in Japan. ...

    Kensuke Usuki, Takayuki Ikezoe, Ken Ishiyama in International Journal of Hematology (2023)

  18. No Access

    Article

    Different effects of thymoglobulin on acute leukemia with pre-transplant residual blasts in HLA mismatch transplantation

    Anti-thymocyte globulin (ATG) is widely used to reduce acute and chronic graft-versus-host disease (a/cGVHD), one of the leading causes of morbidity and mortality after allogeneic hematopoietic stem cell trans...

    Manabu Wakamatsu, Makoto Murata, Junya Kanda in International Journal of Hematology (2023)

  19. Article

    Open Access

    Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma

    In the phase 2 KarMMa trial, patients with relapsed/refractory multiple myeloma (RRMM) achieved deep and durable responses with idecabtagene vicleucel (ide-cel), a B-cell maturation antigen-directed chimeric a...

    Daisuke Minakata, Tadao Ishida, Kiyoshi Ando in International Journal of Hematology (2023)

  20. No Access

    Article

    Decision analysis of allogeneic bone marrow transplantation versus immunosuppressive therapy for young adult patients with aplastic anemia

    Allogeneic bone marrow transplantation (BMT) from an HLA-matched sibling donor is recommended as an initial treatment for young patients. However, immunosuppressive therapy (IST) with cyclosporine and anti-thy...

    Yoshinobu Kanda, Kensuke Usuki, Mitsuhiro Inagaki in International Journal of Hematology (2023)

previous disabled Page of 8